Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Juno Therapeutics has paid roughly $44 million in a mix of cash and stock to acquire X-Body, a Waltham, Mass.-based biotech firm with protein-engineering technology. Juno uses several different approaches to reengineer a patient’s own T cells to home in on and kill cancer cells. The X-Body purchase adds to a buying spree for Juno. In recent weeks, the Seattle-based firm shelled out $70 million for Germany’s Stage Cell Therapeutics, an expert in cellular therapy manufacturing, and paid $25 million up front to access Editas Medicine’s gene-editing capabilities.
This article has been sent to the following recipient: